相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
Steven Fishbane et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
Maiara Camotti Montanha et al.
CLINICAL PHARMACOKINETICS (2022)
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansS
Heather Eng et al.
DRUG METABOLISM AND DISPOSITION (2022)
Fragment-to-Lead Medicinal Chemistry Publications in 2020
Iwan J. P. de Esch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations
Sameer Urgaonkar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Why 90 % of clinical drug development fails and how to improve it?
Duxin Sun et al.
ACTA PHARMACEUTICA SINICA B (2022)
Strategies for targeting undruggable targets
Gong Zhang et al.
EXPERT OPINION ON DRUG DISCOVERY (2022)
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Nina Kim et al.
CLINICAL CANCER RESEARCH (2022)
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir
Ravi Shankar P. Singh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Nirmatrelvir Plus Ritonavir: First Approval
Yvette N. Lamb
DRUGS (2022)
Ritonavir and COVID-19: pragmatic guidance is important
Laura Waters et al.
LANCET (2022)
Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report
Marios Prikis et al.
TRANSPLANTATION PROCEEDINGS (2022)
Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
Simeon Ruedesheim et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases
Shini S. K. Rubina et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2022)
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
Chao Wang et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2022)
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial
Ard van Veelen et al.
LUNG CANCER (2022)
Multidrug efflux transporter ABCG2: expression and regulation
Samiksha Kukal et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Future of Biotransformation Science in the Pharmaceutical Industry
Valerie M. Kramlinger et al.
DRUG METABOLISM AND DISPOSITION (2021)
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
Michael P. Smolinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Management of Pseudobulbar Affect With Fluoxetine and Dextromethorphan
Rachel E. Bent et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2021)
Cross-species analysis of hepatic cytochrome P450 and transport protein expression
Helen Hammer et al.
ARCHIVES OF TOXICOLOGY (2021)
A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling
Johan Wernevik et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2020)
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero et al.
BLOOD (2020)
Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization
Bart L. DeCorte
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Current status and future directions of high-throughput ADME screening in drug discovery
Wilson Z. Shou
JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)
Design of small molecules targeting RNA structure from sequence
Andrei Ursu et al.
CHEMICAL SOCIETY REVIEWS (2020)
Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review
Manvi Sharma et al.
DRUGS & AGING (2019)
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona et al.
LANCET HAEMATOLOGY (2019)
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity
Stephen M. Stahl
CNS SPECTRUMS (2019)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
Guillermo Garcia-Manero et al.
BLOOD (2019)
Enabling synthesis in fragment-based drug discovery by reactivity mapping: photoredox-mediated cross-dehydrogenative heteroarylation of cyclic amines
Rachel Grainger et al.
CHEMICAL SCIENCE (2019)
Absolute Bioavailability of Osimertinib in Healthy Adults
Karthick Vishwanathan et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
Ken-ichi Umehara et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2018)
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
Karthick Vishwanathan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Drug-related deaths in hospital inpatients: A retrospective cohort study
Eva Montane et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
George A. Ward et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Drug Discovery: Collaborations between Contract Research Organizations and the Pharmaceutical Industry
Victoria A. Steadman
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl)-2-[(2R,5R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)
Christopher N. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
Nicola Squillace et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance
Raghava Choudary Palacharla et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
Emiliano Tamanini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice
Ayahisa Watanabe et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2016)
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies
Luc Dirix et al.
CLINICAL THERAPEUTICS (2016)
Twenty years on: the impact of fragments on drug discovery
Daniel A. Erlanson et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor
Paul A. Dickinson et al.
DRUG METABOLISM AND DISPOSITION (2016)
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Bradley Croy Doak et al.
CHEMISTRY & BIOLOGY (2014)
The essential roles of chemistry in high-throughput screening triage
Jayme L. Dahlin et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase
Dana Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
1-Aminobenzotriazole Modulates Oral Drug Pharmacokinetics through Cytochrome P450 Inhibition and Delay of Gastric Emptying in Rats
Rowan A. Stringer et al.
DRUG METABOLISM AND DISPOSITION (2014)
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
Richard A. Ward et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Albumin Stimulates the Activity of the Human UDP-Glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the Effects Are Enzyme and Substrate Dependent
Nenad Manevski et al.
PLOS ONE (2013)
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Chao Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pharmaceutical Profiling Case Study in Disruption
Edward H. Kerns
ACS MEDICINAL CHEMISTRY LETTERS (2013)
P-glycoprotein Inhibition for Optimal Drug Delivery
Md. Lutful Amin
DRUG TARGET INSIGHTS (2013)
Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727
Aram Oganesian et al.
BLOOD (2013)
The UCSF-FDA TransPortal: A Public Drug Transporter Database
K. M. Morrissey et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle
Alleyn T. Plowright et al.
DRUG DISCOVERY TODAY (2012)
The right compound in the right assay at the right time: an integrated discovery DMPK strategy
Peter Ballard et al.
DRUG METABOLISM REVIEWS (2012)
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Michael M. Hann et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Experiences in fragment-based drug discovery
Christopher W. Murray et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
In Vitro ADME Profiling Using High-Throughput RapidFire Mass Spectrometry: Cytochrome P450 Inhibition and Metabolic Stability Assays
Xiang Wu et al.
JOURNAL OF BIOMOLECULAR SCREENING (2012)
Ritonavir-boosted protease inhibitors in HIV therapy
Mark W. Hull et al.
ANNALS OF MEDICINE (2011)
A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2011)
The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression
Patrick du Souich et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Minimizing matrix effects while preserving throughput in LC-MS/MS bioanalysis
Zhengqi Ye et al.
BIOANALYSIS (2011)
Molecular obesity, potency and other addictions in drug discovery
Michael M. Hann
MEDCHEMCOMM (2011)
Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel
Jin-Oh Kwak et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Accelerating high quality bioanalytical LC/MS/MS assays using fused-core columns
Ethan R. Badman et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Dennis A. Smith et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Lianhong Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles
Katja Strauch et al.
FOOD AND CHEMICAL TOXICOLOGY (2009)
Overview of Therapeutic Drug Monitoring
Ju-Seop Kang et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2009)
Induction effects of ritonavir: Implications for drug interactions
Michelle M. Foisy et al.
ANNALS OF PHARMACOTHERAPY (2008)
Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing
Marina Kacevska et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype
A. Gaedigk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The rule of five revisited: Applying log D in place of log p in drug-likeness filters
Sanjivanjit K. Bhal et al.
MOLECULAR PHARMACEUTICS (2007)
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo extrapolation
Andrew Rowland et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase
Miles Congreve et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action
Linda L. Werling et al.
NEUROLOGIST (2007)
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
L Pusztai et al.
CANCER (2005)
The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens
GW Caldwell et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2005)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
RK Zeldin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy
A Sandler et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of cytochrome P450 2D6: Structure-activity studies using a series of quinidine and quinine analogues
JM Hutzler et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2003)
Quinidine and haloperidol as modifiers of CYP3A4 activity: Multisite kinetic model approach
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2002)
Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries
RD Xu et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2002)
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel
MM Malingré et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
